Our study showed that ICI therapy combined with endostatin therapy exhibits high efficacy and safety, suggesting that such a combination might be a viable treatment option for patients with pre-treated NSCLC in the future. This evidence concerns the gene COL18A1 and non-small cell lung carcinoma.